RxDoctor Payments DataLook up a doctor →

Adam Savage, MD

Pain Medicine · Ardmore, OKNPI 1013150481

Payments from drug & device makers

$11,154in general payments, 2019–2025

Across 389 payments — averaging $28.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Vertos Medical, Inc.$2K
  • Omnia Medical, LLC$1K
  • Boston Scientific$683
  • Relievant Medsystems, Inc.$495
  • Nevro Corp.$375
  • plus $4K from 37 others

What the payments were for

  • Consulting fees$2,01818%
  • Travel & lodging$1,35912%
  • Food & beverage$7,75169%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,154 in reported general payments places this provider in the 80th percentile of 68 pain medicine providers in Oklahoma.

See all pain medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$1,844,455
Medicare patients
1,313
Services billed
41,783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl123$85,325
Buprenorphine203$58,968
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,987$45,333
Pregabalin1,425$34,602
Gabapentin1,257$22,711
Xtampza ErOxycodone Myristate42$16,874
Tramadol Hcl ErTramadol Hcl145$8,708
ButransBuprenorphine18$8,101
MovantikNaloxegol Oxalate16$6,768
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen286$6,531
Tramadol Hcl642$5,163
Morphine Sulfate ErMorphine Sulfate158$4,820
Celecoxib276$4,591
Meloxicam530$3,968
Fentanyl37$3,673

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$254$102,198165 claims
Redhill Biopharma Inc.Movantik$13$6,76816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 68 pain medicine providers in Oklahoma.

Other pain medicine in Ardmore

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →